FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Upsher Smith Laboratories Oxandrolone Tablets Recall

Oxandrolone Tablets, USP, 10 mg, Rx Only, C-III, 60-count bottle, Manufactured for: Ups…

Upsher Smith Laboratories, Inc. · Maple Grove, MN

Risk level
Class III
Reported by FDA
Apr 30, 2014
Recall ID
D-1255-2014
Check your lot numberHow we source this data

Summary

Upsher Smith Laboratories recalled Oxandrolone Tablets starting Apr 14, 2014. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-1255-2014 on Apr 30, 2014. Reason: Labeling: Missing Label; Three cases of product (total of 36 bottles) were packaged without the primary label on the bottle. The cases were, however, packaged in the correct finished product shipper, labeled with the correct shipper bar code label, sealed with tamper-evident tape and erroneously shipped to Upsher-Smith. Status: Terminated.

Why it was recalled

Labeling: Missing Label; Three cases of product (total of 36 bottles) were packaged without the primary label on the bottle. The cases were, however, packaged in the correct finished product shipper, labeled with the correct shipper bar code label, sealed with tamper-evident tape and erroneously shipped to Upsher-Smith.

Product description

Oxandrolone Tablets, USP, 10 mg, Rx Only, C-III, 60-count bottle, Manufactured for: Upsher-Smith Labs, Minneapolis, MN 55447, by: Pharmaceutics International, Inc., Hunt Valley, MD 21031, NDC 0245-0272-06

Lot numbers, UPCs & expiration codes

Lot #2802.042A, Exp. 10/2015

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1255-2014
Classification
Class III
Status
Terminated
Recall initiated
Apr 14, 2014
FDA report date
Apr 30, 2014
Quantity
1,185 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Upsher Smith Laboratories, Inc.

Original FDA data

Every field from FDA enforcement report D-1255-2014, exactly as published.

Show all FDA fields
City
Maple Grove
State
MN
Status
Terminated
Country
United States
Event ID
68049
Address
6701 Evenstad Drive
Code information
Lot #2802.042A, Exp. 10/2015
Postal code
55369
Report date
Apr 30, 2014
Product type
Drugs
Recall number
D-1255-2014
Classification
Class III
Recalling firm
Upsher Smith Laboratories, Inc.
Product quantity
1,185 bottles
Termination date
Jul 1, 2014
Reason for recall
Labeling: Missing Label; Three cases of product (total of 36 bottles) were packaged without the primary label on the bottle. The cases were, however, packaged in the correct finished product shipper, labeled with the correct shipper bar code label, sealed with tamper-evident tape and erroneously shipped to Upsher-Smith.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Oxandrolone Tablets, USP, 10 mg, Rx Only, C-III, 60-count bottle, Manufactured for: Upsher-Smith Labs, Minneapolis, MN 55447, by: Pharmaceutics International, Inc., Hunt Valley, MD 21031, NDC 0245-0272-06
Distribution pattern
Nationwide
Recall initiation date
Apr 14, 2014
Initial firm notification
Telephone
Center classification date
Apr 23, 2014

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1255-2014, published Apr 30, 2014. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls